Skip to main content
SpringerLink
Log in

Clinical implication of p53 mutation in lung cancer

  • Review
  • Published:
Molecular Biotechnology Aims and scope Submit manuscript

Abstract

Lung cancer development involves multiple genetic abnormalities leading to malignant transformation of the bronchial epithelial cells, followed by invasion and metastasis. One of the most common changes is mutation of the p53 tumor suppressor gene. The frequency of p53 alterations in lung cancer is highest in small cell and squamous cell carcinomas. A genetic “signature” of the type of p53 mutations has been associated with carcinogens in cigarette smoke. The majority of clinical studies suggest that lung cancers with p53 alterations carry a worse prognosis, and may be relatively more resistant to chemotherapy and radiation. An understanding of the role of p53 in human lung cancer may lead to more rational targeted approaches for treating this disease. P53 gene replacement is currently under clinical investigation but clearly more effective means of gene deliver to the tumor cells are required. Novel approaches to lung cancer therapy are needed to improve the observed poor patient survival despite current therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Vogelstein, B., Lane, D., and Levine, A. J. (2000) Surfing the p53 network. Nature 408, 307–310.

    Article  PubMed  CAS  Google Scholar 

  2. Raff, M. (1998) Cell suicide for beginners. Nature 396, 119–122.

    Article  PubMed  CAS  Google Scholar 

  3. Leach, F. S., Tokino, T., Meltzer, P., Burrell, M., Oliner, J. D., Smith, S., et al. (1993) p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 53, 2231–2234.

    PubMed  CAS  Google Scholar 

  4. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and Howley, P. M. (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63 1129–1136.

    Article  PubMed  CAS  Google Scholar 

  5. Sherr, C. J. (1998) Tumor surveillance via the ARF-p53 pathway [Review]. Genes Dev. 12, 2984–2992.

    PubMed  CAS  Google Scholar 

  6. Rotman, G. and Shiloh, Y. (1999) ATM: a mediator of multiple responses to genotoxic stress. Oncogene 18, 6135–6144.

    Article  PubMed  CAS  Google Scholar 

  7. Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C. R., Shannon, K. E., et al. (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286, 2528–2531.

    Article  PubMed  CAS  Google Scholar 

  8. Levine, A. J., Momand, J., and Finlay, C. A. (1991) The p53 tumor suppressor gene. Nature 351, 453–456.

    Article  PubMed  CAS  Google Scholar 

  9. Harris, C. C. and Hollstein, M. (1993) Clinical implications of the p53 tumor suppressor gene. N. Eng. J. Med. 329, 1318–1327.

    Article  CAS  Google Scholar 

  10. Hernandez-Boussard, T. M., Rodriguez-Tome, P., Montesano, R., and Hainaut, P. (1999) IARC p53 mutations database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. Hum. Mutat. 14, 1–8.

    Article  PubMed  CAS  Google Scholar 

  11. Sekido, Y., Fong, K. M., and Minna, J. D. (2001) Molecular biology of lung cancer, in Cancer: Principles and Practice of Oncology (DeVita, V. T., Hellman, S., and Rosenberg, S. A., eds.), Lippincott Williams & Wilkins, Philadelphia, pp. 917–925.

    Google Scholar 

  12. Whang-Peng, J., Kao-Shan, C. S., Lee, E. C., Bunn, P. A., Carney, D. N., Gazdar, A. F., and Minna, J. D. (1982) Specific chromosome defect associated with human small-cell lung cancer: deletion 3p(14-23). Science 215, 181–182.

    Article  PubMed  CAS  Google Scholar 

  13. Wistuba, I. I., Behrens, C., Virmani, A. K., Mele, G., Milchgrub, S., Girard, L., et al. (2000) High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 60, 1949–1960.

    PubMed  CAS  Google Scholar 

  14. Takahashi, T., Carbone, D., Nau, M. M., Hida, T., Linnoila, I., Ueda, R., and Minna, J. D. (1992) Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res. 52, 2340–2343.

    PubMed  CAS  Google Scholar 

  15. Li, F. P. and Fraumeni, J. F., Jr. (1969) Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann. Intern. Med. 71, 747–752.

    PubMed  CAS  Google Scholar 

  16. Malkin, D., Li, F. P., Strong, L. C., and Fraumeni, J. F. (1990) Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233–1238.

    Article  PubMed  CAS  Google Scholar 

  17. Kleihues, P., Schauble, B., zur Hausen, A., Estève, J., and Ohgaki, H. (1997) Tumors associated with p53 germline mutations: a synopsis of 91 families. Am. J. Pathol. 150, 1–13.

    PubMed  CAS  Google Scholar 

  18. Nichols, K. E., Malkin, D., Garber, J. E., Fraumeni, J. F., Jr., and Li, F. P. (2001) Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol. Biomarkers Prev. 10, 83–87.

    PubMed  CAS  Google Scholar 

  19. Ishioka, C., Frebourg, T., Yan, Y. X., Vidal, M., Friend, S. H., Schmidt, S., and Iggo, R. (1993) Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat. Genet. 5, 124–129.

    Article  PubMed  CAS  Google Scholar 

  20. Ahrendt, S. A., Halachmi, S., Chow, J. T., Halachmi, N., Yang, S. C., Wehage, S., et al. (1999) Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc. Natl. Acad. Sci. USA 96, 7382–7387.

    Article  PubMed  CAS  Google Scholar 

  21. Takahashi, T., Nau, M. M., Chiba, I. B., Rosenberg, R. K., Vinocour, M., Levitt, M., et al. (1989) p53: a frequent target for genetic abnormalities in lung cancer. Science 246, 491–494.

    Article  PubMed  CAS  Google Scholar 

  22. Chiba, I., Takahashi, T., Nau, M. M., D’Amico, D., Curiel, D. T., Mitsudomi, T., et al. (1990) Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5, 1603–1610.

    PubMed  CAS  Google Scholar 

  23. Takahashi, T., Suzuki, H., Hida, T. S., Ariyoshi, Y., and Ueda, R. (1991) The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 6, 1775–1778.

    PubMed  CAS  Google Scholar 

  24. Hensel, C. H., Xiang, R. H., Sakaguchi, A. Y., and Naylor, S. L. (1991) Use of the single strand conformation polymorphism technique and PCR to detect p53 gene mutations in small cell lung cancer. Oncogene 6, 1067–1071.

    PubMed  CAS  Google Scholar 

  25. Samesima, Y., Matsuno, Y., Hirohashi, S., Shimosato, Y., Mizoguchi, H., Sugimura, T., et al. (1992) Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma. Oncogene 7, 451–457.

    Google Scholar 

  26. D’Amico, D., Carbone, D., Mitsudomi, T., Nau, M., Fedorko, J., Russell, E., et al. (1992) High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 7, 339–346.

    PubMed  CAS  Google Scholar 

  27. Kishimoto, Y., Murakami, Y., Shiraishi, M., Hayashi, K., and Sekiya, T. (1992) Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res. 52, 4799–4804.

    PubMed  CAS  Google Scholar 

  28. Mitsudomi, T., Steinberg, S. M., Nau, M. M., Carbone, D., D’Amico, D., Bodner, S., et al. (1992) p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7, 171–180.

    PubMed  CAS  Google Scholar 

  29. Shipman, R., Schraml, P., Colombi, M., Raefle, G., Dalquen, P., and Ludwig, C. (1996) Frequent TP53 gene alterations (mutation, allelic loss, nuclear accumulation) in primary non-small cell lung cancer. Eur. J. Cancer 32A, 335–341.

    Article  PubMed  CAS  Google Scholar 

  30. Girard, L., Zochbauer-Muller, S., Virmani, A. K., Gazdar, A. F., and Minna, J. D. (2000) Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer and loci clustering. Cancer Res. 60, 4894–4906.

    PubMed  CAS  Google Scholar 

  31. Bennett, W. P., Colby, T. V., Travis, W. D., Borkowski, A., Jones, R. T., Lane, D. P., et al. (1993) p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res. 53, 4817–4822.

    PubMed  CAS  Google Scholar 

  32. Walker, C., Robertson, L. J., Myskow, M. W., Dixon, G. R., and Pendleton, N. (1994) p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas. Br. J. Cancer 70, 297–303.

    PubMed  CAS  Google Scholar 

  33. Mao, L., Hruban, R. H., Boyle, J. O., Tockman, M., and Sidransky, D. (1994) Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res. 54, 1634–1637.

    PubMed  CAS  Google Scholar 

  34. Hung, J., Kishimoto, Y., Sugio, K., Virmani, A., McIntire, D. D., Minna, J. D., and Gazdar, A. F. (1995) Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma [published erratum appears in JAMA 1995]. J. Am. Med. Assoc. 273, 558–563.

    Article  CAS  Google Scholar 

  35. Kishimoto, Y., Sugio, K., Hung, J. Y., Virmani, A. K., McIntire, D. D., Minna, J. D., and Gazdar, A. F. (1995) Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancer. J. Natl. Cancer Inst. 87, 1224–1229.

    Article  PubMed  CAS  Google Scholar 

  36. Sugio, K., Kishimoto, Y., Virmani, A. K., Hung, J. Y., and Gazdar, A. F. (1994) K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res. 54, 5811–5815.

    PubMed  CAS  Google Scholar 

  37. Mao, L., Lee, J. S., Kurie, J. M., Fan, Y. H., Lippman, S. M., Lee, J. J., et al. (1997) Clonal genetic alterations in the lungs of current and former smokers. J. Natl. Cancer Inst. 89, 857–862.

    Article  PubMed  CAS  Google Scholar 

  38. Wistuba, I. I., Lam, S., Behrens, C., Virmani, A. K., Fong, K. M., LeRiche, J., et al. (1997) Molecular damage in the bronchial epithelium of current and former smokers. J. Natl. Cancer Inst. 89, 1366–1373.

    Article  PubMed  CAS  Google Scholar 

  39. Strauss, G., DeCamp, M., Dibiccaro, E., Richards, W., Harpole, D., Healey, E., and Sugarbaker, D. (1995) Lung cancer diagnosis is being made with increasing frequency in former cigarette smokers. Proc. Am. Soc. Clin. Oncol. 14, 362-Abst 1106.

    Google Scholar 

  40. Tong, L., Spitz, M. R., Fueger, J. J., and Amos, C. I. (1996) Lung carcinoma in former smokers. Cancer 78, 1004–1010.

    Article  PubMed  CAS  Google Scholar 

  41. Hernandez-Boussard, T. M. and Hainaut, P. (1998) A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database. Environ. Health Perspect. 106, 385–391.

    Article  PubMed  CAS  Google Scholar 

  42. Suzuki, H., Takahashi, T., Kuroishi, T., Suyama, M., Ariyoshi, Y., and Ueda, R. (1992) p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res. 52, 734–736.

    PubMed  CAS  Google Scholar 

  43. Kondo, K., Tsuzuki, H., Sasa, M., Sumitomo, M., Uyama, T., and Monden, Y. (1996) A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients. J. Surg. Oncol. 61, 20–26.

    Article  PubMed  CAS  Google Scholar 

  44. Takagi, Y., Osada, H., Kuroishi, T., Mitsudomi, T., Kondo, M., Niimi, T., et al. (1998) p53 mutations in non-small-cell lung cancers occurring in individuals without a past history of active smoking. Br. J. Cancer 77, 1568–1572.

    PubMed  CAS  Google Scholar 

  45. Husgafvel-Pursiainen, K., Boffetta, P., Kannio, A., Nyberg, F., Pershagen, G., Mukeria, A., et al. (2000) p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Cancer Res. 60, 2906–2911.

    PubMed  CAS  Google Scholar 

  46. Ahrendt, S. A., Chow, J. T., Yang, S. C., Wu, L., Zhang, M.-J., Jen, J., and Sidransky, D. (2000) Alcohol consumption and cigarette smoking increase the frequency of p53 mutation in non-small cell lung cancer. Cancer Res. 60, 3155–3159.

    PubMed  CAS  Google Scholar 

  47. Brennan, J. A., Boyle, J. O., Koch, W. M., Goodman, S. N., Hruban, R. H., Eby, Y. J., et al. (1995) Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N. Eng. J. Med. 332, 712–717.

    Article  CAS  Google Scholar 

  48. Anderson, L. M., Chabra, S. K., Nerurkar, P. V., Souliotis, V. L., and Kyrtopoulos, S. A. (1995) Alcohol-related cancer risk: a toxicologic hypothesis. Alcohol 12, 97–104.

    Article  PubMed  CAS  Google Scholar 

  49. Denissenko, M. F., Pao, A., Tang, M., and Pfeifer, G. P. (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 274, 430–432.

    Article  PubMed  CAS  Google Scholar 

  50. Smith, L. E., Denissenko, M. F., Bennett, W. P., Li, H., Amin, S., Tang, M., and Pfeifer, G. P. (2000) Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J. Natl. Cancer Inst. 92, 803–811.

    Article  PubMed  CAS  Google Scholar 

  51. Passlick, B., Izbicki, J. R., Reithmüller, G., and Pantel, K. (1994) p53 in non-small cell lung cancer. J. Natl. Cancer Inst. 86, 801–802.

    Article  PubMed  CAS  Google Scholar 

  52. Volm, M. and Mattern, J. (1994) Immunohistochemical detection of p53 in non-small-cell lung cancer (letter). J. Natl. Cancer Inst. 86, 1249.

    Article  PubMed  CAS  Google Scholar 

  53. Lee, J. S., Yoon, A., Kalapurakal, S. K., Ro, J. Y., Lee, J. J., Tu, N., et al. (1995) Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J. Clin. Oncol. 13, 1893–1903.

    PubMed  CAS  Google Scholar 

  54. Morkve, O., Halvorsen, O. J., Skjaerven, R., Stangeland, L., Gulsvik, A., and Laerum, O. D. (1993) Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas. Anticancer Res. 13, 571–578.

    PubMed  CAS  Google Scholar 

  55. Iggo, R., Gatter, K., Bartek, J., Lane, D., and Harris, A. L. (1990) Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335, 675–679.

    Article  PubMed  CAS  Google Scholar 

  56. Bodner, S. M., Minna, J. D., Jensen, S. M., D’Amico, D., Carbone, D., Mitsudomi, T., et al. (1992) Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7, 743–749.

    PubMed  CAS  Google Scholar 

  57. Top, B., Mooi, W. J., Klauer, S. G., Boerrigter, L., Wisman, P., Elbers, M., et al. (1995) Comparative analysis of p53 gene mutations and protein accumulation in human non-small cell lung cancer. Int. J. Cancer 64, 83–91.

    Article  PubMed  CAS  Google Scholar 

  58. Carbone, D. P., Mitsudomi, T., Chiba, I., Piantadosi, S., Rusch, V., Nowak, J. A., et al. (1994) p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. Chest 106, 377S-381S.

    PubMed  CAS  Google Scholar 

  59. Isobe, T., Hiyama, K., Yoshida, Y., Fujiwara, Y., and Yamakido, M. (1994) Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection. Jap. J. Cancer Res. 85, 1240–1246.

    CAS  Google Scholar 

  60. Nishio, M., Koshikawa, T., Kuroishi, T., Suyama, M., Uchida, K., Takagi, Y., et al. (1996) Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J. Clin. Oncol. 14, 497–502.

    PubMed  CAS  Google Scholar 

  61. Vega, F. J., Iniesta, P., Caldes, T., Sanchez, A., Lopez, J. A., de Juan, C., et al. (1997) p53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer. Br. J. Cancer 76, 44–51.

    PubMed  CAS  Google Scholar 

  62. Kandioler-Eckersberger, D., Kappel, S., Mittlbock, M., Dekan, G., Ludwig, C., Janschek, E., et al. (1999) The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 117, 744–750.

    Article  PubMed  CAS  Google Scholar 

  63. Huang, C., Taki, T., Adachi, M., Konishi, T., Higashiyama, M., and Miyake, M. (1998) Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. Oncogene 16, 2469–2477.

    Article  PubMed  CAS  Google Scholar 

  64. Skaug, V., Ryberg, D., Kure, E. H., Arab, M. O., Stangeland, L., Myking, A. O., and Haugen, A. (2000) p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin. Cancer Res. 6, 1031–1037.

    PubMed  CAS  Google Scholar 

  65. McLaren, R., Kuzu, I., Dunnill, M., Harris, A., Lane, D., and Gatter, K. C. (1992) The relationship of p53 immunostaining to survival in carcinoma of the lung. Br. J. Cancer 66, 735–738.

    PubMed  CAS  Google Scholar 

  66. Brambilla, E., Gazzeri, S., Moro, D., de Fromental, C. C., Gouyer, V., Jacrot, M., and Brambilla, C. (1993) The relationship of p53 immunostaining correlates with a poor prognosis in human lung cancer. Am. J. Pathol. 143, 199–220.

    PubMed  CAS  Google Scholar 

  67. Kawasaki, M., Nakanishi, Y., Kuwano, K., Yatsunami, J., Takayama, K., and Hara, N. (1997) The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. Clin. Cancer Res. 3, 1195–1200.

    PubMed  CAS  Google Scholar 

  68. Tseng, J. E., Rodriguez, M., Ro, J., Liu, D., Hong, W. K., and Mao, L. (1999) Gender differences in p53 mutational status in small cell lung cancer. Cancer Res. 59, 5666–5670.

    PubMed  CAS  Google Scholar 

  69. Quinlan, D. C., Davidson, A. G., Summers, C. L., Warden, H. E., and Doshi, H. M. (1992) Accumulation of p53 protein correlates with poor prognosis in human lung cancer. Cancer Res. 52, 4828–4831.

    PubMed  CAS  Google Scholar 

  70. Mitsudomi, T., Oyama, T., Kusano, T., Osaki, T., Nakanishi, R., and Shirakusa, T. (1993) Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J. Natl. Cancer Inst. 85, 2018–2023.

    Article  PubMed  CAS  Google Scholar 

  71. Horio, Y., Takahashi, T., Kuroishi, T., Hibi, K., Suyama, M., Niimi, T., et al. (1993) Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res. 53, 1–4.

    PubMed  CAS  Google Scholar 

  72. Ebina, M., Steinberg, S. M., Mulshine, J. L., and Linnoila, R. I. (1994) Relationship of p53 over-expression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res. 54, 2496–2503.

    PubMed  CAS  Google Scholar 

  73. Fontanini, G., Vignati, S., Bigini, D., Mussi, A., Lucchi, M., Angeletti, C. A., et al. (1995) Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br. J. Cancer 71, 1003–1007.

    PubMed  CAS  Google Scholar 

  74. Harpole, D. H., Herndon, J. E., Wolfe, W. G., Iglehart, J. D., and Marks, J. R. (1995) A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 55, 51–56.

    PubMed  CAS  Google Scholar 

  75. Fujino, M., Akita, H. D., Harada, M., Hiroumi, H., Kinoshita, I., Akie, K., and Kawakami, Y. (1995) Prognostic significance of p53 and ras p21 expression in non small cell lung cancer. Cancer 76, 2457–2463.

    Article  PubMed  CAS  Google Scholar 

  76. Langendijk, J. A., Thunnissen, F. B., Lamers, R. J., de Jong, J. M. A., ten Velde, G. P. M., and Wouters, E. F. M. (1995) The prognostic significance of accumulation of p53 protein in stage III non-small cell lung cancer treated with radiotherapy. Radiother. Oncol. 36, 218–224.

    Article  PubMed  CAS  Google Scholar 

  77. Ohsaki, Y., Toyoshima, E., Fujiuchi, S., Matsui, H., Hirata, S., Miyokawa, N., et al. (1996) bcl-2 and p53 protein expression in non-small cell lung cancers: Correlation with survival time. Clin. Cancer Res. 2, 915–920.

    PubMed  CAS  Google Scholar 

  78. Pappot, H., Francis, D., Brünner, N., Grondahl-Hansen, J., and Osterlind, K. (1996) p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: Relation to prognosis. Clin. Cancer Res. 2, 155–160.

    PubMed  CAS  Google Scholar 

  79. Fontanini, G., Vignati, S., Bigini, D., Mussi, A., Lucchi, M., Chine, S., et al. (1996) Recurrence and death in non-small cell lung carcinomas: A prognostic model using pathological parameters, microvessel count, and gene protein products. Clin. Cancer Res. 2, 1067–1075.

    PubMed  CAS  Google Scholar 

  80. Xu, H.-J., Cagle, P. T., Hu, S.-X., Li, J., and Benedict, W. F. (1996) Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: Potential synergistic effects on prognosis. Clin. Cancer Res. 2, 1169–1176.

    PubMed  CAS  Google Scholar 

  81. Pastorino, U., Andreola, S., Tagliabue, E., Pezzella, F., Incabone, M., Sozzi, G., et al. (1997) Immunocytochemical markers in stage I lung cancer: Relevance to prognosis. J. Clin. Oncol. 15, 2858–2865.

    PubMed  CAS  Google Scholar 

  82. Dalquen, P., Sauter, G., Torhorst, J., Schultheiss, E., Jordan, P., Lehmann, S., et al. (1996) Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma. J. Pathol. 178, 53–58.

    Article  PubMed  CAS  Google Scholar 

  83. Komiya, T., Hosono, Y., Hirashima, T., Masuda, N., Yasumitsu, T., Nakagawa, K., et al. (1997) p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin. Cancer Res. 3, 1831–1835.

    PubMed  CAS  Google Scholar 

  84. Fukuyama, Y., Mitsudomi, T., Sugio, K., Ishida, T., Akazawa, K., and Sugimachi, K. (1997) K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br. J. Cancer 75, 1125–1130.

    PubMed  CAS  Google Scholar 

  85. Giatromanolaki, A., Koukourakis, M. I., Kakolyris, S., Turley, H., O’Byrne, K., Scott, P. A. E., et al. (1998) Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin. Cancer Res. 4, 3015–3024.

    Google Scholar 

  86. Kwiatkowski, D. J., Harpole, D. H., Godleski, J., Herndon, J. E. II., Shieh, D.-B., Richards, W., et al. (1998) Molecular pathologic substaging in 244 Stage I non-small-cell lung cancer patients: Clinical implications. J. Clin. Oncol. 16, 2468–2477.

    PubMed  CAS  Google Scholar 

  87. D’Amico, T. A., Massey, M., Herndon, J. E. II., Moore, M.-B., and Harpole, D. H. (1999) A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers. J. Thorac. Cardiovasc. Surg. 117, 736–743.

    Article  PubMed  CAS  Google Scholar 

  88. Geradts, J., Fong, K. M., Zimmerman, P. V., Maynard, R., and Minna, J. D. (1999) Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin. Cancer Res. 5, 791–800.

    PubMed  CAS  Google Scholar 

  89. Moldvay, J., Scheid, P., Wild, P., Nabil, K., Siat, J., Borrelly, J., et al. (2000) Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin. Cancer Res. 6, 1125–1134.

    PubMed  CAS  Google Scholar 

  90. Murren, J., Glatstein, E., and Pass, H. I. (2001) Small cell lung cancer, in Cancer: Principles & Practice of Oncology (DeVita, V.T., Hellman, S., and Rosenberg, S.A., eds.), Lippincott Williams & Wilkins, Philadelphia, pp. 983–1018.

    Google Scholar 

  91. Ginsberg, R. J., Vokes, E. E., and Rosenzweig, K. (2001) Non-small cell lung cancer, in Cancer: Principles & Practice of Oncology (DeVita, V. T., Hellman, S., and Rosenberg, S. A., eds.), Lippincott Williams & Wilkins, Philadelphia, pp. 925–983.

    Google Scholar 

  92. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847–849.

    Article  PubMed  CAS  Google Scholar 

  93. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849.

    Article  PubMed  CAS  Google Scholar 

  94. Lee, J. M. and Bernstein, A. (1993) p53 mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci. USA 90, 5742–5746.

    Article  PubMed  CAS  Google Scholar 

  95. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957–967.

    Article  PubMed  CAS  Google Scholar 

  96. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W.-W., Owen-Schaub, L. B., and Roth, J. A. (1994) Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 54, 2287–2291.

    PubMed  CAS  Google Scholar 

  97. Fan, S., El-Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., et al. (1994) p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 54, 5824–5830.

    PubMed  CAS  Google Scholar 

  98. O’Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., et al. (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlation with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57, 4285–4300.

    PubMed  CAS  Google Scholar 

  99. Wu, G. S. and El-Deiry, W. S. (1996) Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin. Cancer Res. 2, 623–633.

    PubMed  CAS  Google Scholar 

  100. Tsai, C.-M., Chang, K.-T., Wu, L.-H., Chen, J.-Y., Mitsudomi, T., Chen, M.-H., and Perng, R.-P. (1996) Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res. 56, 206–209.

    PubMed  CAS  Google Scholar 

  101. Wahl, A. F., Donaldson, K. L., Fairchild, C., Lee, F. Y., Foster, S. A., Demers, G. W., and Galloway, D. A. (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2-M arrest and apoptosis. Nature Med. 2, 72–79.

    Article  PubMed  CAS  Google Scholar 

  102. Wu, G. S. and El-Deiry, W. S. (1996) p53 and chemosensitivity. Nature Med. 2, 255–256.

    PubMed  CAS  Google Scholar 

  103. Righetti, S. C., Della Torre, G., Pilotti, S., Menard, S., Ottone, F., Colnaghi, M. I., et al. (1996) A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 56, 689–693.

    PubMed  CAS  Google Scholar 

  104. Elledge, R. M., Gray, R., Mansour, E., Yu, Y., Clark, G. M., Ravdin, P., et al. (1995) Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluoruracil, and prednisone for breast cancer. J. Natl. Cancer Inst. 87, 1254–1256.

    Article  PubMed  CAS  Google Scholar 

  105. Rusch, V., Klimstra, D., Venkatraman, E., Oliver, J., Martini, N., Gralla, R., et al. (1995) Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res. 55, 5038–5042.

    PubMed  CAS  Google Scholar 

  106. Matsuzoe, D., Hideshima, T., Kimura, A., Inada, K., Watanabe, K., Akita, Y., et al. (1999) p53 mutations predict non-small cell lung carcinoma response to radiotherapy. Cancer Lett. 135, 189.

    Article  PubMed  CAS  Google Scholar 

  107. King, T. C., Akerley, W., Fan, A. C., Moore, T., Mangray, S., Chen, M. H., and Safran, H. (2000) p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. Cancer 89, 769–773.

    Article  PubMed  CAS  Google Scholar 

  108. De Leo, A. B., Jay, G., Appela, E., Dubois, G. C., Law, L. W., and Old, L. J. (1979) Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. USA 76, 2420–2424.

    Article  Google Scholar 

  109. Crawford, L. V., Pim, D. C., and Bulbrook, R. D. (1982) Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer 30, 403–408.

    Article  PubMed  CAS  Google Scholar 

  110. Soussi, T. (2000) p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 60, 1777–1788.

    PubMed  CAS  Google Scholar 

  111. Lubin, R., Zalcman, G., Bouchei, L., Bouchet, L., Tredaniel, J., Legros, Y., et al. (1995) Serum p53 antibodies as early markers of lung cancer. Nature Med. 11, 701–702.

    Google Scholar 

  112. Schlichtholz, B., Trédaniel, J., Lubin, R., Zalcman, G., Hirsch, A., and Soussi, T. (1994) Analysis of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br. J. Cancer 69, 809–816.

    PubMed  CAS  Google Scholar 

  113. Trivers, G. E., De Benedetti, V. M. G., Cawley, H. L., Caron, G., Harrington, A. M., Bennet, W. P., et al. (1996) Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin. Cancer Res. 2, 1767–1775.

    PubMed  CAS  Google Scholar 

  114. Winter, S. F., Minna, J. D., Johnson, B. E., Takahashi, T., Gazdar, A. F., and Carbone, D. P. (1992) Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res. 52, 4168–4168.

    PubMed  CAS  Google Scholar 

  115. Wild, C. P., Ridanpaa, M., Anttila, S., Lubin, R., Soussi, T., Husgafvel-Pursiainen, K., and Vainio, H. (1995) p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. Int. J. Cancer 64, 176–181.

    Article  PubMed  CAS  Google Scholar 

  116. Davidoff, A. M., Inglehart, J. D., and Marks, J. R. (1992) Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc. Natl. Acad. Sci. USA 89, 3439–3442.

    Article  PubMed  CAS  Google Scholar 

  117. Lubin, R., Schlichtholz, B., Bengoufa, D., Zalcman, G., Tredaniel, J., Hirsch, A., et al. (1993) Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res. 53, 5872–5876.

    PubMed  CAS  Google Scholar 

  118. Angelopoulou, K., Diamandis, E. P., Sutherland, D. J. A., Kellen, J. A., and Bunting, P. S. (1994) Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int. J. Cancer 58, 480–487.

    Article  PubMed  CAS  Google Scholar 

  119. Komiya, T., Hirashima, T., Takada, M., Masuda, N., Yasumitsu, T., Nakagawa, K., et al. (1997) Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung. Anticancer Res. 17, 3721–3724.

    PubMed  CAS  Google Scholar 

  120. Rosenfeld, M. R., Malats, N., Schramm, L., Graus, F., Cardenal, F., Vinolas, N., et al. (1997) Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J. Natl. Cancer Inst. 89, 381–385.

    Article  PubMed  CAS  Google Scholar 

  121. Bergquist, M., Brattstrom, D., Larsson, A., Holmertz, J., Rosenberg, L., Wagenius, G., and Brodin, O. (1998) p53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy. Anticancer Res. 18, 1999–2002.

    Google Scholar 

  122. Mitsudomi, T., Suzuki, S., Yatabe, Y., Nishio, M., Kuwabara, M., Gotoh, K., et al. (1998) Clinical implications of p53 autoantibodies in the sera of patients with non-small cell lung cancer. J. Natl. Cancer Inst. 90, 1563.

    Article  PubMed  CAS  Google Scholar 

  123. Iizasa, T., Fujisawa, T., Saitoh, Y., Hiroshima, K., and Ohwada, H. (1998) Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma. Cancer Immunol. Immunother. 46, 345–349.

    Article  PubMed  CAS  Google Scholar 

  124. Lai, C.-L., Tsai, C.-M., Tsai, T.-T., Kuo, B. I.-T., Chang, K.-T., Fu, H.-T., et al. (1998) Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Clin. Cancer Res. 4, 3025–3030.

    PubMed  CAS  Google Scholar 

  125. Segawa, Y., Kageyama, M., Suzuki, S., Jinno, K., Fujimoto, N., Hotta, K., and Eguchi, K. (1998) Measurement and evaluation of serum anti-p53 antibody levels in patients with lung cancer at its initial presentation: a prospective study. Br. J. Cancer 78, 667.

    PubMed  CAS  Google Scholar 

  126. Laudanski, J., Burzykowski, T., Niklinska, W., Chyczewski, K., Furman, M., and Niklinski, J. (1998) Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer. Lung Cancer 22, 191–200.

    Article  PubMed  CAS  Google Scholar 

  127. Roth, J. A., Nguyen, D., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Ferson, D. Z., et al. (1996) Retrovirus-mediated wildtype p53 gene transfer to tumors of patients with lung cancer. Nature Med. 2, 985–991.

    Article  PubMed  CAS  Google Scholar 

  128. Swisher, S. G., Roth, J. A., Nemunaitis, J., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., et al. (1999) Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 91, 763–771.

    Article  PubMed  CAS  Google Scholar 

  129. Zou, Y., Zong, G., Ling, Y.-H., Hao, M. M., Lozano, G., Hong, W. K., and Perez-Soler, R. (1998) Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. J. Natl. Cancer Inst. 90, 1130–1137.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine, University of Pennsylvania, Clinical Research Buiding 437A, 415 Curie Blvd, 19104, Philadelphia, PA

    Wafik S. El-Deiry

Authors
  1. Barbara G. Campling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wafik S. El-Deiry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wafik S. El-Deiry.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Campling, B.G., El-Deiry, W.S. Clinical implication of p53 mutation in lung cancer. Mol Biotechnol 24, 141–156 (2003). https://doi.org/10.1385/MB:24:2:141

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/MB:24:2:141

Index Entries

Search

Navigation